Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin + Topotecan/Cyclophosphamide in Relapsed/Refractory Pediatric Solid and CNS Tumors
NCT02390843Phase 1Completed
- Sponsor
- Emory University
- Start
- Feb 2015
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simvastatin in retinoblastoma (Rb), clear cell sarcoma (CCS), renal cell carcinoma (RCC) and 10 more, sponsored by Emory University. Primary endpoints: Maximum Tolerated Dose of Simvastatin up to 24 months and Number of Dose-Limiting Toxicities up to 24 months. Started Feb 2015; status: completed.
02
Drugs
simvastatin
03
Conditions
retinoblastoma (Rb)clear cell sarcoma (CCS)renal cell carcinoma (RCC)malignant rhabdoid tumor (MRT)Wilms' tumor
Beyond the preview
Go deeper on NCT02390843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390843.